This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
Sep 14, 2026
•
4 min read
🧬 Scholar Rock's Isembyld (apitegromab) wins FDA approval for spinal muscular atrophy following Ph3 success, Novo Nordisk rebrands to Novo, repositions amid GLP-1 market struggles against Eli Lilly, GSK, Hansoh Pharmaceutical's (risvutatug rezetecan) cuts death risk 54% in Ph3 relapsed small-cell lung cancer trial
Sep 12, 2026
7 min read
[Republished Feature] Grove Biopharma uses protein-like polymers to deliver peptides inside cells, opening the door to drug targets that have long been considered unreachable.
Sep 11, 2026
3 min read
🧬 Handa Oncology receives FDA final approval for Omcazio (cabozantinib) across multiple oncology indications including renal cell carcinoma, EnterpriseSG launches Boston biotech hub in Kendall Square, targeting life sciences partnerships with Massachusetts firms, Argonaut Manufacturing Services divests life sciences, diagnostics unit to 1315 Capital, forming Aluris Sciences
Sep 10, 2026
🧬 FDA expands Bayer's Hyrnuo (zipalertinib) approval to first-line HER2-mutant non-small cell lung cancer via Ph1/2 data, Frazier Life Sciences nets $1.1B for public fund targeting small, mid-cap biotechs, CordenPharma expands aseptic fill-finish capacity to 500 million sterile injectable units annually with €80M ($93.1M) investment
Sep 9, 2026
🧬 Sandoz invests $2.5B to build vertically integrated biosimilar manufacturing network, targeting 100 biosimilars by 2040, Amgen's Imdelltra (tarlatamab-dlle) meets Ph3 OS endpoint as maintenance therapy for extensive-stage small-cell lung cancer, FDA names permanent CBER and CDER heads, signaling leadership stability amid ongoing agency restructuring
Sep 8, 2026
🧬 AstraZeneca's Etcamah (camizestrant) wins FDA approval for ESR1-mutated hormone receptor-positive, HER2-negative advanced breast cancer following Ph3 trial, Bristol Myers Squibb's (arlocabtagene autoleucel) Ph3 trial meets primary endpoint in GPRC5D-targeted relapsed or refractory multiple myeloma, BrainChild Bio raises $116M venture financing to develop CAR-T therapies for childhood brain cancers
Sep 4, 2026
2 min read
🧬 FDA approves Ionis Pharmaceuticals' Zanvastro (zilganersen) as first GFAP-targeting therapy for Alexander disease following Ph3 success, Menarini Group, Gan & Lee Pharmaceuticals partner on GLP-1 bofanglutide European commercialization, $72M upfront, $771M milestones, Superluminal Medicines raises $60M, advancing AI-discovered MC4R drug for rare obesity
Sep 3, 2026
🧬 uniQure submits US marketing application for Huntington's gene therapy AMT-130, seeking accelerated approval, Summit Therapeutics, Akeso's (ivonescimab) beats Merck's Keytruda in Ph3 overall survival and progression-free survival in non-small cell lung cancer, GSK, HUTCHMED partner on HMPL-A830 cancer therapy, $110M upfront, up to $1.3B total
Sep 2, 2026
🧬 AstraZeneca, Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) plus Roche's Perjeta wins EU approval for first-line HER2-positive metastatic breast cancer, Novartis licenses Alteogen ALT-B4 hyaluronidase tech for subcutaneous drug formulations, up to $3.2B, AstraZeneca, HUTCHMED's Tagrisso (osimertinib) plus Orpathys (savolitinib) shows Ph3 win in first-line MET-overexpressing non-small-cell lung cancer
Sep 1, 2026
🧬 Novartis' Rhapsido (remibrutinib) hits Ph3 goals in relapsing multiple sclerosis with no liver safety signal, Roche, Simcere Zaiming partner on B cell disease T cell engager SIM0660, $75M upfront, $1.53B milestones, White House strikes MFN drug pricing deals with Alcon, Astellas Pharma, BridgeBio, Teva Pharmaceuticals, and five other midsized drugmakers
Aug 31, 2026
🧬 Eli Lilly to acquire Merida Biosciences for up to $2.9B, expanding autoimmune and allergic disease pipeline, Takeda, Protagonist Therapeutics' Mimrylo (rusfertide) wins FDA approval for polycythemia vera following Ph3 success, Jazz Pharmaceuticals' Ziihera (zanidatamab) achieves second overall survival win in Ph3 HER2-positive gastroesophageal adenocarcinoma trial
Aug 28, 2026
🧬 FDA approves Eli Lilly's Mounjaro (tirzepatide) GLP-1/GIP agonist for cardiovascular risk reduction in type 2 diabetes, Bristol Myers Squibb invests $173M to build second radiopharmaceutical manufacturing plant in Indiana, Priovant Therapeutics' Lisraya (brepocitinib) wins first FDA approval as targeted TYK2/JAK1 inhibitor tablet for dermatomyositis
Aug 27, 2026
🧬 Revolution Medicines' Rasonque (daraxonrasib) wins FDA approval for second-line pancreatic ductal adenocarcinoma, targeting RAS, AstraZeneca, Amgen's Tezspire (tezepelumab) hits Ph3 endpoints in eosinophilic esophagitis, targeting TSLP pathway, Artis BioSolutions opens Spanish facility, expanding synthetic DNA and mRNA production capabilities for genetic medicines
Aug 26, 2026
🧬 FDA approves Jazz Pharmaceuticals' Ziihera (zanidatamab) as first-line HER2-targeted therapy for gastroesophageal adenocarcinoma based on Ph3 data, Biohaven, SK Biopharmaceuticals partner on Kv7 epilepsy platform licensing deal worth up to $795M, FDA considers adding two deputy commissioner roles focused on AI/health and drugs
Aug 25, 2026
🧬 FDA grants Capricor Therapeutics three-month extension to review (deramiocel) Ph3 data for Duchenne muscular dystrophy upper limb indication, Johnson & Johnson's Imaavy (nipocalimab) gains FDA label expansion for warm autoimmune hemolytic anemia backed by Ph2/3 data, Eli Lilly launches oral obesity pill Foundayo in UK, challenging Novo Nordisk's head-start Wegovy pill
Aug 24, 2026
🧬 Roche, Hanmi Pharm partner on weight loss drug HM17321, $190M upfront, up to $2.3B deal, Lundbeck reports 16% sales growth in H1 2026, driven by Vyepti and Rexulti gains, Spruce Biosciences advances toward Q4 FDA filing for ultra-rare Sanfilippo syndrome drug after successful manufacturing talks
Aug 21, 2026
🧬Roche invests $750M to double Oregon Genentech facility, adding fill-finish manufacturing capacity by 2031, Werewolf Therapeutics, Ambros Therapeutics merge in $150M deal targeting rare CRPS-1 pain disorder, Aurinia Pharmaceuticals settles with Teva Pharmaceuticals, protecting Lupkynis from generics until December 2036
Aug 20, 2026
🧬 Ultragenyx wins first gene therapy FDA approval for Genglycos (DTX401) targeting glycogen storage disease type Ia via Ph3, Kynexis raises €97M ($113M) Series A, advancing cognitive impairment schizophrenia drug to registrational development, Regeneron wins FDA approval for Pasatru (garetosmab) targeting Activin A in fibrodysplasia ossificans progressiva based on Ph3 data
Aug 19, 2026
🧬 Merck & Co., Moderna's intismeran autogene (mRNA-4157) plus Keytruda (pembrolizumab) reduces recurrence risk in Ph3 melanoma trial, Trump nominates White House aide Heidi Overton as new FDA commissioner, CSL shares surge 17% on immunoglobulin demand recovery and stronger-than-expected $15.8B revenue
Aug 18, 2026
🧬 Amylyx Pharmaceuticals eyes FDA filing for (avexitide) after Ph3 win in post-bariatric hypoglycemia, BioMarin Pharmaceutical acquires Alesta Therapeutics for $275M to challenge AstraZeneca in rare bone disease market, Biokin Pharma's (iza-bren) EGFRxHER3 bispecific ADC meets Ph3 primary endpoint in EGFR-mutated nonsquamous non-small cell lung cancer
Aug 17, 2026
🧬 Vera Therapeutics' Trutakna shows kidney function stabilization in Ph3, rivaling Otsuka's Voyxact in immunoglobulin A nephropathy, Slate Medicines reverse merges with Fulcrum Therapeutics, raises $245M for migraine antibody trials on Nasdaq, AstraZeneca's Tagrisso (osimertinib) plus Orpathys (savolitinib) meets PFS and overall survival goals in Ph3 EGFR-mutated non-small-cell lung cancer trial
Aug 14, 2026
🧬 FDA grants Bristol Myers Squibb accelerated approval for Zenbexus (iberdomide), a CELMoD agent, for multiple myeloma, Vogenx raises $81.3M IPO, clinical-stage biopharma targeting metabolic serious diseases, Capricor Therapeutics soars after FDA greenlights amendment to DMD cell therapy approval application
Aug 13, 2026
🧬 PTC Therapeutics acquires Sangamo Therapeutics' Fabry gene therapy for $111M upfront, $100M milestones, Taiho Pharmaceutical, Cullinan Therapeutics' (zipalertinib) EGFR inhibitor meets Ph3 primary endpoint in first-line non-small cell lung cancer, Akeso's ivonescimab wins China Ph3-backed approval for first-line squamous non-small-cell lung cancer
Aug 12, 2026
🧬 BridgeBio's Attruby hits $222M quarterly sales, nearing blockbuster status as ATTR stabilizer-first market emerges, Definium Therapeutics' DT120 (LSD) succeeds in Ph3 trial for generalized anxiety disorder, InduPro raises $77M Series B, backed by Sanofi and Lilly, funding cancer pipeline advancement
Aug 11, 2026
🧬 Bristol Myers Squibb commits $2.3B to build Houston manufacturing campus, creating 2,500 jobs, Jazz Pharmaceuticals to acquire Actio Biosciences for up to $1.3B, expanding rare epilepsy pipeline, Vaderis Therapeutics raises $152M Series B to advance AKT-targeting HHT treatment
